Iron tablets every other day compared with daily for iron deficiency anemia
Compares ferrous fumarate taken daily or every other day in adults with iron deficiency anemia.
Key facts
- Who runs it
- Phramongkutklao College of Medicine and Hospital
- Where
- Thailand1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Alternate-Day vs. Once-Daily Oral Iron Supplementation in Iron Deficiency Anemia (IDA)
- Status
- Recruiting
- People taking part
- 60 people, planned
- Started
- 9 Jun 2025
- Expected to end
- 31 Dec 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Ferrous Fumarate Oral Tablet
- Record updated
- 14 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with iron deficiency anemia (low blood count from too little iron). It compares iron tablets taken every day with iron tablets taken every other day.
- Age
- 20 years or older
- Sex
- Men and women
- Disease stage
- Iron deficiency anemia: hemoglobin <13 g/dL in men or <12 g/dL in women.
- Earlier treatment
- No iron supplements in the past 3 months. No red blood cell transfusion in the past 3 months.
- Biomarker or test result
- Ferritin <50 ng/mL or transferrin saturation (TSAT) <20%.
Main reasons for not taking part
- Unstable circulation, such as acute bleeding or low blood pressure
- Severe heart failure (NYHA Class III-IV) or other active heart disease
- Active cancer or cancer in the past 3 years, except non-melanoma skin cancer
- Pregnancy or breastfeeding
- Chronic kidney disease (eGFR <60 mL/min/1.73 m²), serious liver disease, thalassemia, ongoing infection, chronic inflammation or poor gut absorption
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Male or female patients aged ≥20 years diagnosed with iron deficiency anemia, defined as: hemoglobin (Hb) <13 g/dL in males or <12 g/dL in females, and ferritin <50 ng/mL or transferrin saturation (TSAT) <20%
- No iron supplementation within the past 3 months
Who cannot take part
- Occurrence of severe complications, such as symptomatic anemia or circulatory collapse, requiring intravenous iron therapy or blood transfusion
- Hemodynamic instability (e.g., acute bleeding or hypotension)
- Severe heart failure (New York Heart Association [NYHA] Class III-IV) or other active cardiac diseases
- Active malignancy or history of cancer within the past 3 years (except non-melanoma skin cancer)
- Chronic liver disease including cirrhosis (Child-Pugh class B or C)
- Ongoing infection or chronic inflammatory diseases (e.g., rheumatoid arthritis, inflammatory bowel disease)
- Malabsorption disorders (e.g., history of bariatric surgery)
- Occurrence of severe adverse events that render the participant unable to tolerate oral iron, even after dose reduction; Treatment Failure
- Chronic kidney disease (estimated glomerular filtration rate [eGFR] <60 mL/min/1.73 m²)
- Hemoglobin level decreases by 1 g/dL or more compared to baseline at Week 4 or Week 8
- Blood hemoglobin level increases by less than 1 g/dL following the evaluation at Week 4 or Week 8, which is considered treatment failure
- Increase in hemoglobin level of < 1 g/dL at Week 4 or Week 8 compared with baseline
- Pregnancy or breastfeeding
- Clinically significant thalassemia or hemoglobinopathies
- Red blood cell transfusion within the past 3 months; Withdrawal Criteria
- The participant requests to withdraw from the research study
This trial is currently available in Thailand.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal of this clinical trial is to compare the effectiveness and tolerability of two different oral iron regimens in adults with iron deficiency anemia (IDA). The main questions it aims to answer are:
Read full original descriptionShow less
Is alternate-day oral iron supplementation as effective as once-daily dosing in improving hemoglobin levels?
What are the side effects associated with each dosing regimen?
Researchers will compare once-daily vs. alternate-day oral ferrous fumarate to evaluate whether alternate-day dosing is non-inferior in terms of hematologic response, with fewer adverse effects.
Participants will:
Be randomly assigned to take ferrous fumarate 200 mg once daily or 400 mg on alternate days for 8 weeks
Undergo blood tests and clinical assessments at baseline, Week 4, and Week 8
Report any side effects and bring remaining pills to evaluate medication adherence
This is a multicenter, randomized, open-label, non-inferiority trial conducted in adults aged 20 years or older with IDA.
The 2 groups in the trial
- Once-Daily Dosing GroupExisting treatment, for comparison
Participants will receive ferrous fumarate 200 mg, taken orally once daily for 8 weeks. This arm represents the standard dosing regimen for treating iron deficiency anemia (IDA). Participants will be monitored at baseline, Week 4, and Week 8 for blood counts, iron parameters, and adverse effects. Medication adherence will be assessed using pill counts.
Treatment: Ferrous Fumarate Oral Tablet
- Alternate-Day Dosing GroupTreatment being tested
Participants will receive ferrous fumarate 400 mg (two 200 mg tablets), taken orally on alternate days for 8 weeks. This dosing strategy is being evaluated for improved iron absorption and fewer gastrointestinal side effects compared to daily dosing. Participants will be monitored at baseline, Week 4, and Week 8 for blood counts, iron parameters, and adverse effects. Medication adherence will be assessed using pill counts.
Treatment: Ferrous Fumarate Oral Tablet
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Alternate-Day vs. Once-Daily Oral Iron Supplementation in Iron Deficiency Anemia (IDA): A Randomized, Open-Label, Non-Inferiority Trial
- Plain-language title
- Iron tablets every other day compared with daily for iron deficiency anemiaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Record updated
- 14 October 2026